Mriglobal

COMMUNITY PROJECT FUNDING/CONGRESSIONALLY DIRECTED SPENDING - CONSTRUCTION - THE FOCUS OF THIS GRANT APPLICATION IS AN EXPANSION OF THE LIFE SCIENCES CAPABILITY AT MRIGLOBAL'S OWNED HEADQUARTERS FACILITY LOCATED AT 425 DR. MARTIN LUTHER KING JR. BOULEVARD. MRIGLOBAL’S HEADQUARTERS IS A MODERN 225,000 SQ. FT. FACILITY THAT INCLUDES 60,000 SQ. FT. OF SCIENTIFIC LABORATORY SPACE PLUS ADMINISTRATIVE OFFICES AND OTHER CAPABILITIES SUPPORTING MRIGLOBAL’S MISSION TO USE SCIENCE AND TECHNOLOGY TO CREATE SOLUTIONS FOR A SAFER, HEALTHIER, MORE SUSTAINABLE WORLD. THIS LIFE SCIENCES CAPABILITY EXPANSION PROJECT IS INTENDED TO ADVANCE MRIGLOBAL’S ABILITY TO SUPPORT HUMAN HEALTH THROUGH RESEARCH PROJECTS CONDUCTED FOR MULTIPLE NIH ORGANIZATIONS, INCLUDING NCI, NIAID, NINDS, NIEHS, AND NCATS, AS WELL ASL THE CDC AND FDA. THE PROPOSED INVESTMENT WILL PROVIDE FUNDING TO PURCHASE SCIENTIFIC LABORATORY EQUIPMENT AND LABORATORY INFRASTRUCTURE TO EXPAND OUR OFFERINGS TO CURRENT AND PROSPECTIVE CUSTOMERS. THIS INVESTMENT WILL ADVANCE R&D IN NEW AND INVESTIGATIONAL DRUGS AND NEW TECHNOLOGIES IN MEDICAL TREATMENTS. MRIGLOBAL IS A 501C3 NOT-FOR-PROFIT ORGANIZATION THAT CONDUCTS MORE THAN $110M/YEAR OF RESEARCH FOR FEDERAL AND COMMERCIAL CUSTOMERS. OUR FEDERAL RESEARCH EFFORTS SUPPORT INITIATIVES FOR THE DEPARTMENT OF HEALTH AND HUMAN SERVICES AND THE DEPARTMENT OF DEFENSE. MRIGLOBAL IS COMMITTED TO REMAINING WELL-POSITIONED TO ADVANCE THE HEALTH AND SAFETY OF OUR WORLD. MRIGLOBAL’S GROWTH AMBITION TO DOUBLE ITS IMPACT OVER THE NEXT DECADE WILL POSITIVELY IMPACT THE REGIONAL KANSAS CITY ECONOMY BY GROWING THE NUMBER OF HIGH PAYING JOBS AND SERVICES, MAINTAINING OUR LEADERSHIP AS A STRONG AND ACTIVE CORPORATE CITIZEN, AND CONTINUING TO SUPPORT KANSAS CITY'S SCIENCE, TECHNOLOGY, ENGINEERING AND MATH EDUCATION PROGRAMS AND WORKFORCE DEVELOPMENT. MRIGLOBAL WAS OPTIMALLY POISED TO RESPOND TO THE PRIORITY NEEDS OF THE GLOBAL COVID-19 CRISIS. WE SUPPORTED SAFETY AND EFFICACY EVALUATION OF CANDIDATE TREATMENTS FOR COVID-19, TESTING OF DISINFECTANT TECHNOLOGIES, MASK EVALUATIONS, DEVELOPMENT/APPLICATION OF COVID-19 DIAGNOSTIC TESTING, DEVELOPING BACK-TO-WORK/SCHOOL SAFETY PLANS FOR ACADEMIC INSTITUTIONS AND DEPLOYING SEVERAL MOBILE LABORATORIES AND CONTAINMENT UNITS TO PANDEMIC RESPONSE EFFORTS. THIS INVESTMENT WILL ALLOW MRIGLOBAL TO CONTINUE TO ADDRESS THESE URGENT NATIONAL AND GLOBAL HEALTH PROGRAMS WITHOUT A LAPSE OF SUPPORT TO OTHER FEDERAL CLIENTS WITH PRIORITY NEEDS IN AREAS OF WARFIGHTER PROTECTION, BIOSURVEILLANCE FOR PATHOGENS, RESEARCH TO SUPPORT ADVANCEMENT OF THERAPEUTICS AND VACCINES FOR CANCER, NEUROLOGICAL HEALTH AND OTHER INFECTIOUS DISEASES.

GENOTYPIC PHENOTYPIC ANALYSIS OF RIFT VALLEY FEVER VIRUS SERIALLY PASSED IN VITRO AND IN VIVO

COMMUNITY PROJECT FUNDING/CONGRESSIONALLY DIRECTED SPENDING - CONSTRUCTION - THE FOCUS OF THIS GRANT APPLICATION IS ENHANCING THE RESILIENCY OF MRIGLOBAL’S BIOREPOSITORY CAPABILITY AT AN OWNED FACILITY LOCATED AT 1222 OZARK STREET, NORTH KANSAS CITY (NKC), MO. MRIGLOBAL’S NKC FACILITY IS A MODERN 87,000 SQ. FT. FACILITY THAT INCLUDES A SOPHISTICATED BIOREPOSITORY, CGMP PHARMACEUTICAL WAREHOUSE SPACE, ADMINISTRATIVE OFFICES, AND OTHER CAPABILITIES SUPPORTING MRIGLOBAL’S MISSION TO USE SCIENCE AND TECHNOLOGY TO CREATE SOLUTIONS FOR A SAFER, HEALTHIER, MORE SUSTAINABLE WORLD. THIS BIOREPOSITORY RESILIENCY INVESTMENT WILL ADVANCE MANAGEMENT OF BIOLOGICS, BIOLOGICAL SAMPLES (BIOSPECIMENS), AND THE REGIONAL SUPPLY CHAIN SUPPORTING CLINICAL STUDIES AIMED AT ADVANCING THE NEWEST TECHNOLOGIES IN MEDICAL TREATMENTS AND DISEASE PREVENTION. MRIGLOBAL’S GROWTH OVER THE NEXT DECADE WILL POSITIVELY IMPACT THE REGIONAL KANSAS CITY ECONOMY BY INCREASING THE NUMBER OF HIGH PAYING JOBS AND SERVICES, MAINTAINING OUR LEADERSHIP AS A STRONG AND ACTIVE CORPORATE CITIZEN, AND CONTINUING TO SUPPORT THE KANSAS CITY REGION’S SCIENCE, TECHNOLOGY, ENGINEERING AND MATH (STEM) EDUCATION PROGRAMS AND WORKFORCE DEVELOPMENT. MRIGLOBAL IS A 501C3 NOT-FOR-PROFIT ORGANIZATION THAT CONDUCTS MORE THAN $110M/YEAR OF RESEARCH FOR FEDERAL AND COMMERCIAL CUSTOMERS. OUR FEDERAL RESEARCH EFFORTS SUPPORT INITIATIVES FOR THE DEPARTMENT OF HEALTH AND HUMAN SERVICES AND THE DEPARTMENT OF DEFENSE. MRIGLOBAL IS COMMITTED TO REMAINING WELL-POSITIONED TO ADVANCE THE HEALTH AND SAFETY OF OUR WORLD. FOR EXAMPLE, WE WERE OPTIMALLY POISED TO RESPOND TO THE PRIORITY NEEDS OF THE GLOBAL COVID-19 CRISIS. WE SUPPORTED SAFETY AND EFFICACY EVALUATION OF CANDIDATE TREATMENTS FOR COVID-19, TESTING OF DISINFECTANT TECHNOLOGIES, MASK EVALUATIONS, DEVELOPMENT/APPLICATION OF COVID-19 DIAGNOSTIC TESTING, DEVELOPING BACK-TO-WORK/SCHOOL SAFETY PLANS FOR ACADEMIC INSTITUTIONS AND DEPLOYING SEVERAL MOBILE LABORATORIES AND CONTAINMENT UNITS TO PANDEMIC RESPONSE EFFORTS. WITH CONTINUED INVES TMENT, MRIGLOBAL WILL CONTINUE TO OPERATE AT FOREFRONT OF DISEASE PREVENTION, TREATMENT, AND RESEARCH.

PURPOSE: ECONOMIC DEVELOPMENT INITIATIVE, COMMUNITY PROJECT FUNDING/CONGRESSIONAL DIRECTED SPENDING AWARDS ARE AUTHORIZED UNDER THE CONSOLIDATED APPROPRIATIONS ACT, 2022 PUBLIC LAW 117-328 AND THE EXPLANATORY STATEMENT FOR DIVISION L OF THAT ACT. PROJECTS SELECTED FOR COMMUNITY PROJECT FUNDING/CONGRESSIONAL DIRECTED SPENDING ARE LISTED IN THE JOINT EXPLANATORY STATEMENT (JES) THAT ACCOMPANIES A SPECIFIC FISCAL YEAR’S APPROPRIATIONS ACT OR CONGRESSIONAL RECORD. THE JES LISTS PROJECT, RECIPIENT, STATE, AMOUNT AND CONGRESSIONAL SPONSOR.; ACTIVITIES TO BE PERFORMED: ECONOMIC DEVELOPMENT INITIATIVE, COMMUNITY PROJECT FUNDING/CONGRESSIONALLY DIRECTED SPENDING AWARD PROJECTS INCLUDE A WIDE VARIETY OF ACTIVITIES THAT RESULT IN ECONOMIC DEVELOPMENT OR COMMUNITY DEVELOPMENT OUTCOMES. HUD WILL NOT KNOW THE FULL SCOPE OF THE PROJECT UNTIL THE RECIPIENT SUBMITS THE REQUIRED PROJECT NARRATIVE AND CONFIRMS ALIGNMENT WITH THE LANGUAGE AS PROVIDED IN THE CONGRESSIONAL RECORD. TO FIND THE DETAILS OF THE GRANT AWARD AS WRITTEN WITHIN THE CONGRESSIONAL RECORD USE THE FOLLOWING LINK AND PATH SELECTIONS TO GET TO THE DESCRIPTION OF THE ECONOMIC DEVELOPMENT INITIATIVE, COMMUNITY PROJECT FUNDING GRANTS HTTPS://WWW.HUD.GOV/PROGRAM_OFFICES/COMM_PLANNING/EDI-GRANTS, SELECT THE FISCAL YEAR OF INTEREST, SCROLL DOWN TO PROGRAM LAWS AND REGULATIONS, UNDER FISCAL YEAR 20XX CONSOLIDATED APPROPRIATIONS ACT, 20XX: CONGRESSIONAL RECORD (JOINT EXPLANATORY STATEMENT).; EXPECTED OUTCOMES: COMPLETION OF THE PROJECT AS DESCRIBED IN THE JOINT EXPLANATORY STATEMENT (JES) PROJECT DESCRIPTION AND SUBSEQUENT APPROVED PROJECT NARRATIVE.; INTENDED BENEFICIARIES: THE PROJECT BENEFICIARIES ARE THE INDIVIDUALS AND/OR ORGANIZATIONS THAT ARE AWARDED GRANT FUNDS OR SERVED BY THE ENTITIES THAT ARE AWARDED GRANT FUNDS AS IDENTIFIED IN THE JES RECIPIENT OR PROJECT DESCRIPTION SECTIONS.; SUBRECIPIENT ACTIVITIES: THE SUBRECIPIENT ACTIVITIES ARE UNKNOWN AT THE TIME OF AWARD.

BW POWDERED AGENTY VULNERABILITY ASSESSMENT

MODELING DISTRIBUTION OF INSECTICIDAL AEROSOLS IN MILLS AND PROCESSING FACILITIES

IN THIS COLDTECH PROJECT A SOLID-STATE NANOPORE INSTRUMENT WILL BE DEVELOPED FOR THE DETECTION AND STUDY OF BIOMARKERS FOR MICROBIAL LIFE IN OCEAN WORLD ENVIRONMENTS. THE SEQUENCING OF LIFE ON OCEAN WORLDS (SEQLOW) INSTRUMENT IS A SOLID-STATE NANOPORE PLATFORM DESIGNED FOR THE DETECTION AND CHARACTERIZATION OF POLYANIONIC AND POLYCATIONIC POLYMERS. SEQLOW HERITAGE IS DERIVED FROM OXFORD NANOPORE S MINION INSTRUMENT A COMMERCIAL OFF THE SHELF (COTS) PRODUCT. THE MINION IS A SMALL PORTABLE DNA SEQUENCING PLATFORM THAT CONSISTS OF PROTEIN NANOPORES EMBEDDED IN AN ELECTRICALLY RESISTANT POLYMER MATERIAL. THE MINION IS THIRD GENERATION SEQUENCING TECHNOLOGY AND IS ROBUST ENOUGH FOR IN SITU FIELD ANALYSIS HERE ON EARTH. THE SYSTEM IS SLATED TO BE TESTED ON THE INTERNATIONAL SPACE STATION IN THE SUMMER OF 2016. HOWEVER THE INTEGRITY OF THE CURRENT PROTEIN NANOPORE MEMBRANE USED IN THE MINION IS NOT SUFFICIENTLY ROBUST TO SURVIVE LONG DURATION SPACE MISSIONS. THE SEQLOW SOLID-STATE NANOPORE PLATFORM WILL ADVANCE CURRENT STATE-OF-THE-ART NANOPORE SENSING TECHNOLOGY AS A LIFE DETECTION INSTRUMENT FOR USE IN FUTURE NASA MISSIONS. SEQLOW COLDTECH DEVELOPMENT GOALS ARE: 1) DEVELOPMENT AND FABRICATION OF ROBUST SOLID-STATE NANOPORE MEMBRANES WITH ARRAYS OF DIFFERENT PORE DIAMETERS FOR DETECTION OF MULTIPLE TYPES OF BIOMARKERS (I.E. DNA CHARGED PROTEINS AMINO ACIDS ETC.). 2) INTEGRATION OF THE SEQLOW MEMBRANES INTO A MICROFLUIDIC PLATFORM FOR IN SITU LIFE DETECTION. MICROFLUIDICS WILL BE USED TO CARRY OUT SAMPLE PROCESSING CONCENTRATION AND DELIVERY OF THE SAMPLE MATERIAL TO THE SOLID-STATE MEMBRANE FOR ANALYSIS. TECHNOLOGIES AND METHODS WILL BE DEVELOPED FOR SENSOR OPERATION DURING DEEP SPACE MISSIONS THAT ELIMINATE: A) LOSS OF ANALYTE INTEGRITY B) DISRUPTION OF NANOPORE APERTURE OR C) DISRUPTION OF PORE CURRENT BY SAMPLE INTERFERENCES. SEQLOW DIRECTLY ADDRESSES THE GOALS OF THE COLDTECH PROGRAM AND NASA BY DEVELOPMENT OF SPACECRAFT-BASED INSTRUMENTS AND TECHNOLOGY FOR SURFACE AND SUBSURFACE EXPLORATION OF OCEAN WORLDS SUCH AS EUROPA ENCELADUS AND TITAN. SEQLOW ALSO WILL ADDRESS THE NASA PLANETARY SCIENCE DIVISION S STRATEGIC GOALS AND OBJECTIVES AND IS FOCUSED ON THE DETECTION OF EXTANT LIFE IN THE OCEAN WORLDS OF THE OUTER SOLAR SYSTEM.